论文部分内容阅读
目的:探讨普罗布考对动脉粥样硬化性脑梗死并高脂血症患者血脂及预后的影响。方法:将87例脑梗死并高脂血症患者随机分为两组,治疗组44例,对照组43例,两组除按动脉粥样硬化性脑梗死常规治疗外,停用一切降脂药物。治疗组给予普罗布考500 mg bid/d。疗程为6个月。随访一年观察两组患者治疗后血脂水平及脑血管事件发生情况。结果:治疗组患者治疗前、后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)间差异均有显著性意义(P<0.05)。两组患者治疗后各项血脂指标间差异均有显著性意义(P<0.05)。随访一年,显示治疗组患者心脑血管事件14次,对照组19次(P<0.05)。结论:普罗布考降脂疗效可靠、副作用轻微,降低心脑血管事件发生。可作为动脉粥样硬化性脑梗死并高脂血症患者的一、二级预防药物。
Objective: To investigate the effect of probucol on blood lipid and prognosis in patients with atherosclerotic cerebral infarction and hyperlipidemia. Methods: Eighty-seven patients with cerebral infarction and hyperlipidemia were randomly divided into two groups: 44 cases in the treatment group and 43 cases in the control group. All the patients except the routine treatment of atherosclerotic cerebral infarction were stopped using all lipid-lowering drugs . The treatment group was given probucol 500 mg bid / d. The course of treatment is 6 months. One year follow-up observed two groups of patients after treatment of blood lipid levels and cerebrovascular events. Results: The differences of total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL) before and after treatment in the treatment group were significant (P <0.05). There was significant difference between the two groups of blood lipid indicators after treatment (P <0.05). One year follow-up showed that the treatment group had 14 cardiovascular and cerebrovascular events and 19 control subjects (P <0.05). Conclusion: Probucol has a reliable lipid-lowering effect with minor side effects and reduces cardiovascular and cerebrovascular events. Can be used as primary and secondary prevention of atherosclerotic cerebral infarction and hyperlipidemia patients.